# Blueprint Medicines Corporation: Phase 2 study closed enrollment, 251 enrolled (Indolent Systemic Mastocytosis)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Blueprint Medicines Corporation |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis |
| NCT ID | NCT03731260 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Indolent Systemic Mastocytosis |
| Intervention types | drug |
| Target enrollment | 251 |
| Site countries | United States, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland |
| Posted | 2018-11-06 |
| Planned start | 2019-04-16 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-02 |
| Last update posted | 2026-10-02 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 251 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03731260). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.